🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

PulmonologyICD-10: J44

Find Recruiting Clinical Trials for COPD

Search COPD exacerbation prevention, bronchodilator, and disease-modification trials — matched to your lung function and exacerbation history.

🔍 Search COPD Trials →

About COPD

Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disease causing persistent airflow obstruction, primarily caused by long-term exposure to tobacco smoke or air pollutants. It affects approximately 16 million diagnosed Americans and 384 million globally. COPD encompasses chronic bronchitis and emphysema. Current treatments improve symptoms and reduce exacerbations but do not halt disease progression. Acute exacerbations — sudden worsening episodes — are the primary cause of hospitalization, morbidity, and mortality.

What Types of COPD Clinical Trials Exist?

COPD clinical trials address multiple unmet needs. Exacerbation prevention trials test inhaled triple therapy (LABA/LAMA/ICS) optimization, biologics targeting type 2 inflammation (dupilumab, itepekimab for eosinophilic COPD), and anti-inflammatory agents. Lung function preservation trials test phosphodiesterase inhibitors and novel anti-fibrotic/anti-inflammatory approaches. Rehabilitation and digital health trials test pulmonary rehabilitation optimization. GOLD stage (spirometry-based), exacerbation frequency, and blood eosinophil count are key eligibility determinants.

Find Recruiting COPD Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search COPD Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for COPD?▾
Recruiting COPD trials include biologic therapies for eosinophilic COPD (dupilumab, itepekimab), triple inhaled therapy optimization, phosphodiesterase-4 inhibitors, mucolytic agents, lung volume reduction interventions, pulmonary rehabilitation optimization, and digital health management programs. Frequent exacerbator phenotypes have the most active trial options.
What GOLD stage do I need for COPD trials?▾
GOLD staging (1–4) is based on post-bronchodilator FEV1: GOLD 1 (≥80%), GOLD 2 (50–79%), GOLD 3 (30–49%), GOLD 4 (<30%). Most drug trials enroll GOLD 2–3 (moderate-severe COPD). Some trials specifically enroll frequent exacerbators (≥2 moderate or ≥1 severe exacerbation in the prior year) regardless of exact GOLD stage.
Can current smokers join COPD clinical trials?▾
Many COPD trials require smoking cessation — either as an eligibility criterion (ex-smoker or stopped within a defined period) or as a strong recommendation. Some trials accept current smokers. Smoking status directly affects lung function and inflammatory markers, so it is a standard eligibility and stratification variable.

Related Conditions

AsthmaPulmonary FibrosisLung Cancer

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.